Stryker Co. (NYSE:SYK) Receives Average Rating of “Moderate Buy” from Brokerages

Stryker Co. (NYSE:SYK) has received an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $331.52.

Several brokerages recently weighed in on SYK. Roth Mkm increased their price objective on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Wells Fargo & Company raised their price target on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Royal Bank of Canada restated an “outperform” rating and issued a $360.00 price target on shares of Stryker in a research note on Thursday, February 15th. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and raised their price objective for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st.

Stryker Stock Down 0.2 %

Shares of SYK stock opened at $357.87 on Friday. Stryker has a 1-year low of $249.98 and a 1-year high of $361.41. The stock’s fifty day moving average price is $343.42 and its 200 day moving average price is $305.60. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The company has a market cap of $135.97 billion, a price-to-earnings ratio of 43.38, a price-to-earnings-growth ratio of 2.86 and a beta of 0.89.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 earnings per share. On average, research analysts expect that Stryker will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio is 38.79%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 3,273 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

Several hedge funds have recently added to or reduced their stakes in SYK. Burkett Financial Services LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA increased its stake in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 61 shares in the last quarter. Quarry LP bought a new stake in shares of Stryker in the 1st quarter valued at $27,000. Rogco LP bought a new stake in shares of Stryker in the 4th quarter valued at $30,000. Finally, Clear Street Markets LLC bought a new stake in shares of Stryker in the 4th quarter valued at $30,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.